Amendment: SEC Form SC 13D/A filed by BioAtla Inc.

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D/A

Under the Securities Exchange Act of 1934

(Amendment No. 6)

BioAtla, Inc.

(Name of Issuer)

Common Stock, $0.0001 par value

(Title of Class of Securities)

09077B104

(CUSIP Number)

Soleus Private Equity GP I, LLC

104 Field Point Road, 2^nd Floor

Greenwich, CT 06830

Attn: Steven J. Musumeci

(475) 208-3178

(Name, Address and Telephone Number of Person Authorized
to Receive Notices and Communications)

October 1, 2024

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box ☐.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 09077B104

CUSIP No. 09077B104

CUSIP No. 09077B104

CUSIP No. 09077B104

CUSIP No. 09077B104

CUSIP No. 09077B104 

CUSIP No. 09077B104

CUSIP No. 09077B104

EXPLANATORY NOTE

This Amendment No. 6 to Schedule 13D (this “Amendment”) is being filed by the Reporting Persons named in Item 2 below with respect to the beneficial ownership of the Reporting Persons in BioAtla, Inc., a Delaware corporation. This amendment supplements the Schedule 13D as previously filed on December 28, 2020 (as amended by that certain Amendment No. 1 to Schedule 13D filed on June 28, 2021, that certain Amendment No. 2 to Schedule 13D filed on September 3, 2021, that certain Amendment No. 3 to Schedule 13D filed on January 9, 2023, that certain Amendment No. 4 to Schedule 13D filed on April 16, 2024, and that certain Amendment No. 5 to Schedule 13D filed on September 6, 2024, the “Schedule 13D”). Each Item below amends and restates the information disclosed under the corresponding Item of the Schedule 13D. Unless otherwise indicated herein, capitalized terms used but not defined in this Amendment shall have the same meaning herein as are ascribed to such terms in the Schedule 13D.

Item 1. Security and Issuer.

The title of the class of equity securities to which this statement relates is the common stock, par value $0.0001 per share (“Common Stock”), of BioAtla, Inc., a Delaware corporation (the “Issuer”). The Issuer’s principal executive offices are located at 11085 Torreyana Road, San Diego, CA 92121.

Item 2. Identity and Background.

(a) This statement is a joint filing by Soleus Private Equity Fund I, L.P. (“Soleus LP”), Soleus Private Equity GP I, LLC (“Soleus GP”), Soleus PE GP I, LLC (“Soleus PE GP”), Soleus Capital Master Fund, L.P. (“Master Fund”), Soleus Capital, LLC (“Soleus Capital”), Soleus Capital Group, LLC (“Soleus Capital Group”) and Guy Levy (each of the foregoing, individually, a “Reporting Person”, and collectively, the “Reporting Persons”).

Soleus PE GP is the sole manager of Soleus GP. Soleus GP is the sole general partner of Soleus LP. Mr. Guy Levy is the sole managing member of Soleus PE GP. Soleus GP holds voting and dispositive power over the shares held by Soleus LP. Each of Mr. Guy Levy, Soleus GP and Soleus PE GP disclaims beneficial ownership of the securities held by Soleus LP, and this report shall not be deemed an admission that they are the beneficial owners of such shares for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or for any other purpose, except to the extent of their respective pecuniary interests therein.

Soleus Capital is the sole general partner of Master Fund. Soleus Capital Group is the sole managing member of Soleus Capital. Mr. Guy Levy is the sole managing member of Soleus Capital Group. Soleus Capital holds voting and dispositive power over the shares held by Master Fund. Each of Mr. Guy Levy, Soleus Capital Group and Soleus Capital disclaims beneficial ownership of the securities held by Master Fund, and this report shall not be deemed an admission that they are the beneficial owners of such shares for purposes of Section 13(d) of the Exchange Act, or for any other purpose, except to the extent of their respective pecuniary interests therein.

Each Reporting Person disclaims beneficial ownership of all securities reported herein except to the extent of such Reporting Person’s pecuniary interest therein and other than those securities reported herein as being held directly by such Reporting Person.

(b) The principal office and business address of the Reporting Persons is 104 Field Point Road, 2^nd Floor, Greenwich, CT 06830.

(c) The principal business of the Reporting Persons is to invest in equity and equity-related securities and other securities of any kind or nature. Mr. Levy is the sole managing member of Soleus PE GP and Soleus Capital Group, as well the founder, Chief Executive Officer and Chief Investment Officer of Soleus Capital Management, L.P., the investment manager of Soleus LP and Master Fund. Mr. Levy also served as a member of the Board of Directors of the Issuer from July 2020 until June 2022.

(d) and (e) The Reporting Persons have not, during the last five years, been (a) convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors), or (b) party to a civil proceeding of a judicial or administrative body of competent jurisdiction as a result of which it or he is or was subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

(f) Each of Soleus GP, Soleus PE GP, Soleus Capital and Soleus Capital Group is a Delaware limited liability company. Soleus LP is a Delaware limited partnership. Master Fund is a Cayman Islands limited partnership. Mr. Guy Levy is a citizen of the United States.

Item 3. Source and Amount of Funds or Other Consideration.

Item 3 of the original Schedule 13D, as amended, is hereby incorporated herein by reference.

Item 4. Purpose of Transaction.

The Reporting Persons hold the securities of the Issuer for general investment purposes. The Reporting Persons may, from time to time, depending on prevailing market, economic and other conditions, acquire additional shares of Common Stock or other securities of the Issuer, dispose of any such securities, or engage in discussions with the Issuer concerning such acquisitions or dispositions or further investments in the Issuer. The Reporting Persons intend to review their investment in the Issuer on a continuing basis and, depending upon the price and availability of shares of Common Stock or other securities of the Issuer, subsequent developments affecting the Issuer, the Issuer’s business and prospects, other investment and business opportunities available to the Reporting Persons, general stock market and economic conditions, tax considerations and other factors considered relevant, may decide at any time to increase or to decrease the size of their investment in the Issuer in the open market, in privately negotiated transactions, pursuant to 10b5-1 trading plans or otherwise.

As noted above, Mr. Guy Levy served as a member of the Board of Directors of the Issuer from July 2020 until June 2022. In his capacity as a director of the Issuer, Mr. Levy was entitled to receive cash and/or equity compensation pursuant to the Issuer’s director compensation programs as were in effect from time to time.

Except as set forth herein, the Reporting Persons have no present plan or proposal that relates to or would result in any other action specified in clauses (a) through (j) of Item 4 of Schedule 13D.

Item 5. Interest in Securities of the Issuer.

(a) As of the close of business on October 1, 2024, the Reporting Persons beneficially own an aggregate of 1,237,909 shares of Common Stock, representing approximately 2.56% of the outstanding shares of Common Stock (based upon 48,335,737 shares of Common Stock outstanding as of August 2, 2024, as reported on the cover of the Issuer’s Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2024 that was filed with the Securities and Exchange Commission on August 8, 2024. Of the shares of Common Stock owned by the Reporting Persons:

(b) Soleus GP is the sole general partner of Soleus LP, Soleus PE GP is the sole manager of Soleus GP, and Mr. Guy Levy is the sole managing member of Soleus PE GP. In such capacities, Soleus GP, Soleus PE GP and Mr. Guy Levy have the shared power to vote or to direct the vote, and to dispose or to direct the disposition of, all of the securities held by Soleus LP that are reported herein. However, each of Mr. Guy Levy, Soleus GP and Soleus PE GP disclaims beneficial ownership of the securities held by Soleus LP, and this report shall not be deemed an admission that they are the beneficial owners of such shares for purposes of Section 13(d) of the Exchange Act, or for any other purpose, except to the extent of their respective pecuniary interests therein.

Soleus Capital is the sole general partner of Master Fund, Soleus Capital Group is the sole managing member of Soleus Capital, and Mr. Guy Levy is the sole managing member of Soleus Capital Group. In such capacities, Soleus Capital, Soleus Capital Group and Mr. Guy Levy have the shared power to vote or to direct the vote, and to dispose or to direct the disposition of, all of the securities held by Master Fund that are reported herein. However, each of Mr. Guy Levy, Soleus Capital Group and Soleus Capital disclaims beneficial ownership of the securities held by Master Fund, and this report shall not be deemed an admission that they are the beneficial owners of such shares for purposes of Section 13(d) of the Exchange Act, or for any other purpose, except to the extent of their respective pecuniary interests therein.

(c) On September 6, 2024, Master Fund sold an aggregate of 1,500 shares of Common Stock and Soleus LP sold an aggregate of 340 shares of Common Stock, in each case, at a price of $1.86 per share, in open market transactions.

On September 9, 2024, Master Fund sold an aggregate of 76,134 shares of Common Stock and Soleus LP sold an aggregate of 19,000 shares of Common Stock, in each case at a price of $1.86 per share, in open market transactions.

On September 19, 2024, Master Fund sold an aggregate of 15,922 shares of Common Stock and Soleus LP sold an aggregate of 4,000 shares of Common Stock, in each case at a price of $1.77 per share, in open market transactions.

On September 20, 2024, Master Fund sold an aggregate of 400 shares of Common Stock and Soleus LP sold an aggregate of 60 shares of Common Stock, in each case at a price of $1.75 per share, in open market transactions.

On September 24, 2024, Master Fund sold an aggregate of 2,938 shares of Common Stock and Soleus LP sold an aggregate of 700 shares of Common Stock, in each case at a price of $1.75 per share, in open market transactions.

On September 30, 2024, Master Fund sold an aggregate of 8,000 shares of Common Stock and Soleus LP sold an aggregate of 2,000 shares of Common Stock, in each case at a price of $1.75 per share, in open market transactions.

On October 1, 2024, Master Fund sold an aggregate of 1,023,700 shares of Common Stock and Soleus LP sold an aggregate of 255,869 shares of Common Stock, in each case at a price of $1.88 per share, in open market transactions.

Other than the foregoing transactions, and he transactions reflected in Amendment No. 5 to the Schedule 13D filed on September 6, 2024, none of the Reporting Persons have effected any transactions in the Issuer’s Common Stock during the 60 days preceding the date of this Amendment.

(d) Under certain circumstances set forth in the limited partnership agreements and/or operating agreements, as applicable, of each of Soleus LP and Master Fund, the general partner, managing member, limited partners and/or members, as applicable, of such entities may be deemed to have the right to receive dividends from, or the proceeds from, the sale of shares of the Issuer owned by such entity of which they are a partner or member, as applicable.

(e) Not applicable.

Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of Issuer.

Item 6 of the original Schedule 13D is hereby incorporated herein by reference.

Item 7. Materials to be Filed as Exhibits.

SIGNATURE

After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

Dated: October 2, 2024

13